CME GROUP INC. (CME) — SEC Filings

Latest SEC filings for CME GROUP INC. (CME), explained in plain English.

Sentiment Overview: 3 bullish, 36 neutral, 1 mixed

Recent Filings (40)

• CME Group Files Additional Proxy Materials on March 23, 2026 — DEFA14A · 2026-03-23T16:17:52-04:00 [neutral]
  CME Group Inc. filed a DEFA14A on March 23, 2026, which is an additional definitive proxy soliciting material. This filing, identified by SEC Accession No. 0001
• CME Group Files 2025 Annual Report to Security Holders — ARS · 2026-03-23T16:16:50-04:00 [neutral]
  CME Group Inc. (CIK: 0001156375) filed its Annual Report to Security Holders (ARS) on March 23, 2026, for the fiscal year ending December 31, 2025. This routine
• CME Group Q3 Revenue Dips, Investment Income Boosts Net Profit — 10-Q · 2025-10-24T00:00:00.000Z [mixed] Risk: medium
  CME Group Inc. reported a slight decrease in total revenues for the quarter ended September 30, 2025, falling to $1,537.6 million from $1,584.4 million in the p
• CME Group Inc. Files 8-K on Financials — 8-K · 2025-10-22T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. filed an 8-K on October 22, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. T
• CME Group Inc. Files 8-K for Executive and Director Changes — 8-K · 2025-09-11T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. announced on September 9, 2025, changes in its executive and director compensation arrangements. The filing details the departure of a director,
• CME Group's Q2 Revenue Jumps to $1.29B on Strong Trading Fees — 10-Q · 2025-07-25T00:00:00.000Z [bullish] Risk: low
  CME Group Inc. reported a robust financial performance for the second quarter of 2025, with total revenue reaching $1,287 million, a significant increase from $
• CME Group Inc. Files 8-K on Financials — 8-K · 2025-07-23T00:00:00.000Z [neutral] Risk: low
  On July 23, 2025, CME Group Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as fina
• CME Group Inc. Files 8-K on Security Holder Vote — 8-K · 2025-05-09T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. filed an 8-K on May 9, 2025, reporting on a matter submitted to a vote of security holders on May 8, 2025. The filing details the company's princ
• CME Group Q1 2025: Assets Top $360M — 10-Q · 2025-04-30T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's total assets stood at $360,356,107, with total liabilities of $625.
• CME Group Inc. Enters Material Definitive Agreement — 8-K · 2025-04-25T00:00:00.000Z [neutral] Risk: medium
  On April 23, 2025, CME Group Inc. entered into a material definitive agreement, creating a direct financial obligation. The filing, dated April 25, 2025, detail
• CME Group Inc. Files 8-K on Financials — 8-K · 2025-04-23T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. filed an 8-K on April 23, 2025, reporting on its results of operations and financial condition, and including financial statements and exhibits.
• CME Group Inc. Files 8-K Report — 8-K · 2025-04-14T00:00:00.000Z [neutral] Risk: low
  On April 14, 2025, CME Group Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific fi
• CME Group Proxy Statement Filed — DEFA14A · 2025-03-25T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. has filed a Definitive Proxy Statement (DEFA14A) for the fiscal year ending December 31, 2024. The filing includes information regarding the elec
• CME Group Files 2025 Proxy Statement — DEF 14A · 2025-03-20T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. filed its definitive proxy statement (DEF 14A) on March 20, 2025, for its 2025 annual meeting. The filing outlines the company's governance, exec
• CME Group Inc. Files 8-K Report — 8-K · 2025-03-10T00:00:00.000Z [neutral] Risk: low
  On March 10, 2025, CME Group Inc. filed an 8-K report, indicating the entry into a material definitive agreement and the filing of financial statements and exhi
• CME Group Files 8-K Report — 8-K · 2025-03-04T00:00:00.000Z [neutral] Risk: low
  On March 3, 2025, CME Group Inc. filed an 8-K report to disclose other events and financial statements. The filing does not contain specific details about the n
• CME Group Inc. Files 2024 Annual Report — 10-K · 2025-02-27T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. filed its 2024 10-K on February 27, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, headquar
• CME Group Inc. Files 8-K on Financials — 8-K · 2025-02-12T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. filed an 8-K on February 12, 2025, reporting on its results of operations and financial condition, and providing financial statements and exhibit
• CME Group Files 8-K Report — 8-K · 2024-12-11T00:00:00.000Z [neutral] Risk: low
  On December 11, 2024, CME Group Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No speci
• CME Group Inc. Files 8-K Report — 8-K · 2024-12-05T00:00:00.000Z [neutral] Risk: low
  On December 5, 2024, CME Group Inc. filed an 8-K report. The filing primarily serves as a notification of other events and includes financial statements and exh
• SC 13G/A Filing — SC 13G/A · 2024-11-08T00:00:00.000Z [neutral]
• CME Group Q3 Revenue Rises to $1.01B — 10-Q · 2024-11-08T00:00:00.000Z [bullish] Risk: low
  CME Group Inc. reported its third-quarter results for the period ending September 30, 2024. The company's total revenue for the nine months ended September 30,
• CME Group Files 8-K on Officer/Director Changes & Compensation — 8-K · 2024-11-07T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. filed an 8-K on November 7, 2024, reporting on events that occurred on November 6, 2024. The filing includes information regarding the departure
• CME Group Inc. Files 8-K on Financials — 8-K · 2024-10-23T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. filed an 8-K on October 23, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements a
• SC 13G/A Filing — SC 13G/A · 2024-10-22T00:00:00.000Z [neutral]
• CME Group Q2 Earnings: $1.287B Net Income — 10-Q · 2024-08-05T00:00:00.000Z [bullish] Risk: low
  CME Group Inc. reported its financial results for the period ending June 30, 2024. The company's total assets stood at $360.09 billion, with total liabilities a
• CME Group Inc. Files 8-K with Financial Updates — 8-K · 2024-07-24T00:00:00.000Z [neutral] Risk: low
  On July 24, 2024, CME Group Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits relat
• CME Group Appoints John P. McNulty to Board — 8-K · 2024-07-08T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. announced on July 8, 2024, the appointment of John P. McNulty as a new Class II Director, effective immediately. McNulty, who will serve on the A
• CME Group Inc. Files 8-K on Shareholder Vote Matters — 8-K · 2024-05-13T00:00:00.000Z [neutral] Risk: low
  On May 9, 2024, CME Group Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing, submitted on May 13, 2024, perta
• CME Group Q1 Revenue Hits $1.29B, EPS at $1.15 — 10-Q · 2024-05-01T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. reported its first quarter 2024 results, with total revenues reaching $1.287 billion. The company's diluted earnings per share were $1.15 for the
• CME Group Inc. Enters Material Definitive Agreement — 8-K · 2024-04-25T00:00:00.000Z [neutral] Risk: medium
  On April 24, 2024, CME Group Inc. entered into a material definitive agreement related to a direct financial obligation. The filing does not provide specific de
• CME Group Inc. Files 8-K on Financials — 8-K · 2024-04-24T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. filed an 8-K on April 24, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhi
• CME Group Proxy Statement Filed — DEFA14A · 2024-03-21T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. filed a Definitive Proxy Statement (DEFA14A) on March 21, 2024, detailing its 2024 Class B campaign letters. The filing includes information rela
• CME Group Files 2024 Proxy Statement — DEFA14A · 2024-03-19T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. has filed its Definitive Proxy Statement (DEFA14A) for its 2024 annual meeting. The filing, dated March 19, 2024, outlines the company's governan
• CME Group Inc. Files 2023 DEF 14A — DEF 14A · 2024-03-18T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. filed its DEF 14A on March 18, 2024, for the fiscal year ending December 31, 2023. The filing details executive compensation and other corporate
• CME Group Announces Leadership Transition — 8-K · 2024-03-07T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. announced on March 7, 2024, that Terrence A. Duffy will transition from Executive Chairman and President to Executive Chairman, effective March 1
• CME Group Files 2023 10-K, Details Debt Maturities and Rates — 10-K · 2024-02-28T00:00:00.000Z [neutral] Risk: low
  CME Group Inc. filed its 10-K on February 28, 2024, for the fiscal year ended December 31, 2023. The company reported a business phone number of 312-930-1000 an
• CME Group Files 8-K for Financial Results and Exhibits — 8-K · 2024-02-14T00:00:00.000Z [neutral] Risk: low
  CME GROUP INC. filed an 8-K on February 14, 2024, to report its Results of Operations and Financial Condition, along with related Financial Statements and Exhib
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• BlackRock Trims CME Group Stake to 10.3% — SC 13G/A · 2024-01-26T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, disclosing its ownership of 37,280,432 shares of CME Group Inc. Class A Common Stock as of Decembe